Drug intelligence / Profile preview

anti-CD45RO antibody

Development stage
Unknown
Modality
Antibody-Based Therapeutics
01

Overview

Anti-CD45RO antibody refers to a class of monoclonal antibodies that target CD45RO, an isoform of the receptor-type protein tyrosine phosphatase C (PTPRC, also known as CD45). CD45RO is the shortest isoform of CD45, lacking exons 4, 5, and 6, and is predominantly expressed on activated and memory T cells, as well as some B cell subsets, activated monocytes, macrophages, and granulocytes. By binding to CD45RO, these antibodies can modulate T-cell receptor (TCR) signaling and have been investigated for their potential to suppress memory T-cell-mediated immune responses. This mechanism is of therapeutic interest for preventing or treating transplant rejection, graft-versus-host disease (GVHD), and autoimmune disorders, where memory T cells drive costimulation-blockade-resistant immune responses. Additionally, anti-CD45RO antibodies (such as clone UCHL1) are widely utilized as research reagents for flow cytometry, immunohistochemistry, and in vitro functional assays to identify and characterize memory T-cell populations.

Other names
CD45RO antibodyCD-45RO antibodyCD 45RO antibodyanti-CD45RO monoclonal antibodyanti-CD-45RO monoclonal antibodyanti-CD 45RO monoclonal antibody
02

Targets

CD22 (Cluster of Differentiation 22)DPP-4 (Dipeptidyl Peptidase-IV)FYN (Proto-oncogene tyrosine-protein kinase Fyn)LCK (Proto-oncogene tyrosine-protein kinase Lck)LYN (LYN proto-oncogene, Src family tyrosine kinase)ZAP70 (Zeta-chain-associated protein kinase 70)CD45RA (T-cell surface glycoprotein CD45 isoform RA)

Beyond the preview

Go deeper on anti-CD45RO antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD45RO antibody.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call